RxDoctor Payments Data

George Durst, MD

Internal Medicine · Ellicott City, MDNPI 1265470876

Payments from drug & device makers

$244in general payments, 2019–2025

Across 15 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$113
  • Medtronic$30
  • Novo Nordisk$29
  • Johnson & Johnson$26
  • Smith+Nephew$21
  • GSK$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)7$113
Medtronic1$30
Novo Nordisk2$29
Johnson & Johnson2$26
Smith+Nephew1$21
GSK1$14
Gilead1$11

How this compares

$244 in reported general payments places this provider in the 50th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$184,990
Medicare patients
498
Services billed
1,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$138,846
OzempicSemaglutide78$126,280
JardianceEmpagliflozin76$100,481
RybelsusSemaglutide26$49,245
Synjardy XrEmpagliflozin/Metformin Hcl44$47,757
XareltoRivaroxaban42$41,970
TrulicityDulaglutide12$23,983
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,623
MounjaroTirzepatide11$19,539
JanuviaSitagliptin Phosphate21$19,052
Breo ElliptaFluticasone/Vilanterol27$17,670
MyrbetriqMirabegron17$15,144
MovantikNaloxegol Oxalate26$15,039
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$14,063
FarxigaDapagliflozin Propanediol13$8,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$29$175,525104 claims
Johnson & JohnsonXarelto$26$41,97042 claims
GSKTrelegy Ellipta, Breo Ellipta$14$41,29356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →